Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2020

View Archived Issues

Cutting off AML's metabolic escape route

Challenges for mutation correction in human embryos

FDA approves Bronchitol inhalation powder for patients with cystic fibrosis

Innovation Pharmaceuticals receives pre-IND response for brilacidin trial in COVID-19

FDA clears IND application for phase I/II study of EG-70 in NMIBC

Adakveo approved in Europe to prevent VOCs in patients with sickle cell disease

Concert initiates phase III THRIVE-AA1 study of CTP-543 for alopecia areata

AT-752 improves survival in mouse model of dengue infection

Nurix Therapeutics patents CBLB inhibitors

Plexxikon discloses KAT3B and CREBBP inhibitors

Bristol Myers Squibb identifies new Gal-3 inhibitors

Nuvation Bio describes new Wee1 inhibitors

Tenaya Therapeutics presents AAV5 compositions

Serine deprivation spurs selective translation in pancreatic cancer

JCR begins global phase I/II trial of JR-171 for MPS I

Combination of donepezil and quetiapine or PDE10A inhibitors provides synergic anti-BuChE activity

Phase III results for molidustat in patients with renal anemia undergoing dialysis

LV20.19, a bispecific CAR T-cell therapy for RR B-cell malignancies: results from phase I trial

Biodistribution, dosimetry and preclinical efficacy data presented for [177Lu]rhPSMA-7.3

New PROTACs synthesized by C4 Therapeutics

BiomX begins first-in-human study of BX-002 phage therapy for IBD

Phase II/III study of voclosporin ophthalmic solution in dry eye does not meet primary endpoint

IO Biotech announces new phase II trial of cancer immunotherapies in head & neck cancer

Aligos begins first-in-human trial of ALG-000184 for chronic hepatitis B

HT-005 reduces skin plaque severity in cutaneous lupus erythematosus mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...